ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO1565

The Impact of Obesity on Glomerulonephritis: A Multicenter Cohort Study of Kidney Biopsy over 40 Years

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Kim, Tae-bum, Korea University Medical Center, Seoul, Korea (the Republic of)
  • Min, Hyeon-Jin, Korea University Medical Center, Seoul, Korea (the Republic of)
  • Son, Young-Bin, Korea University Medical Center, Seoul, Korea (the Republic of)
  • Lee, Jonghyun, Korea University Medical Center, Seoul, Korea (the Republic of)
  • Kim, Myung-Gyu, Korea University Medical Center, Seoul, Korea (the Republic of)
  • Jo, Sang-Kyung, Korea University Medical Center, Seoul, Korea (the Republic of)
  • Cho, Won-Yong, Korea University Medical Center, Seoul, Korea (the Republic of)
  • Bae, Eun Hui, Chonnam National University Medical School, Gwangju, Gwangju, Korea (the Republic of)
  • Oh, Jieun, Hallym University College of Medicine, Chuncheon, Gangwon, Korea (the Republic of)
  • Ahn, Shin-Young, Korea University Medical Center, Seoul, Korea (the Republic of)
  • Oh, Sewon, Korea University Medical Center, Seoul, Korea (the Republic of)
Background

Worldwide obesity has increased by almost three times between 1975 and 2020. Many studies reported that obesity related kidney disease was also increasing, and most of them were focal segmental glomerulosclerosis (FSGS). However, little was known about the prevalence and outcome of other type of glomerulonephritis (GN) in obese patients.

Methods

A total of 14,833 adult patients who underwent kidney biopsy and had body mass index (BMI) were identified in 18 tertiary hospitals during 1979-2018. Obesity was defined as BMI≥30 kg/m2. We analyzed the prevalence of specific forms of glomerulonephritis in obese patients and effect of obesity on mortality and end stage kidney disease (ESKD).

Results

Obese patients in glomerular disease have increased about 12.8-fold over 40 years between 1979-1988 (0.6%) and 2009-2018 (7.7%). In GN patients with obesity, prevalence of IgA nephropathy (IgAN) is the most common (33.7%) followed by FSGS (13.3%), minimal change disease (MCD) (10.8%), membranous nephropathy (10.6%), diabetic nephropathy (DMN)(6.0%), lupus nephritis (LN) (2.7%), and hypertensive nephropathy (HT-N) (2.6%). The prevalence of FSGS (HR 1.60, 95%CI 1.24-2.06), DMN (HR 1.46, 95%CI 1.01-2.12) and HT-N (HR 2.14, 95% CI 1.29-3.54) were significant higher in obese patients compared than non-obese patients. Obesity had a 1.39-fold increased risk for ESKD progression during 93.8±0.8 months follow up in total patients (95%CI 1.11-1.73). Obesity had higher risks for progression of ESKD in MCD (HR 2.48, 95%CI 1.02-6.04) and LN (HR, 3.28, 95% CI 1.30-8.31). In patients with FSGS, DMN, and HT-N, obesity was not associated with ESKD. Obesity was not associated with mortality in GN patients although obesity was related to mortality only in MCD patients (HR 2.48, 95% CI 1.02-6.04).

Conclusion

Obesity rates are increasing in GN patients. The prevalence of FSGS, DMN, and HT-N are significantly higher in obese patients although IgAN is the most common form of GN. Obesity had significant risks for progression of ESKD in patients with GN, especially MCD and LN patients.